Background {#Sec1}
==========

*CDH23*, located on chromosome 10, contains 70 exons and encodes a predicted 3354 amino acid protein. The untranslated region is followed by 27 extracellular cadherin repeat domains (exons 2--64), a single-pass transmembrane domain (exon 65), and a cytoplasmic domain (exons 66--70). Among the 113 human cadherin superfamily members, CDH23 is one of 11 that are solely responsible for hereditary diseases \[[@CR1]\]. CDH23 is expressed in the outer and inner hair cells. The stereociliary expression of CDH23 in inner ear hair cells exhibits two patterns. One is transient expression during the development of hair bundles with procadherin 15 (PCDH15) and CDH23 forming side links and kinociliary links at their N-termini \[[@CR2]\]. The second pattern is stable expression in tip links at the top of stereocilia from the developmental stage onwards until ear maturation. CDH23 homodimers interact *in trans* with PCDH15 homodimers to form filaments, and they play a key role in the mechanoelectrical transduction channel at the top of the lower stereocilia \[[@CR3]-[@CR5]\].

Mutations in *CDH23* are responsible for both Usher syndrome 1D (USH1D: OMIM \#601067) \[[@CR6]-[@CR9]\] and autosomal recessive non-syndromic hearing loss (DFNB12: OMIM \#601386) \[[@CR10]-[@CR12]\]. Individuals with USH1D usually carry a truncated CDH23 protein because of nonsense, frameshift, or splice-site mutations, whereas those with DFNB12 usually carry missense mutations in any domain \[[@CR7],[@CR10],[@CR13]\]. The mutation spectrums differ regionally, with the Japanese population having a unique mutation spectrum \[[@CR12],[@CR14]\]. Recently, it was reported that 3.7% of recessive inherited hearing loss cases in the Japanese population involve homozygous or heterozygous *CDH23* mutations \[[@CR12]\].

In this study, we analyzed *CDH23* in a Japanese population that was selected on the basis of DFNB12 and USH1D clinical features \[[@CR12],[@CR14]-[@CR16]\] after excluding patients with *GJB2* mutations and mitochondrial m.1555A \> G and m.3243A \> G mutations. We identified an extremely high prevalence of *CDH23* mutations in this population, and our findings expanded the *CDH23* mutation spectrum, including five novel mutations.

Methods {#Sec2}
=======

All participating subjects, or their parents if the subjects were less than 20 years old, provided informed consent. The project was approved by the institutional review board of each institute. The patients were collected from the 11 institutes listed below: National Tokyo Medical Center, Chiba Children's Hospital, National Mie Hospital, National Center for Child Health and Development, Hyogo Prefectural Kobe Children's Hospital, Keio University School of Medicine, National Hospital Organization Kanazawa Medical Center, Kanagawa Children's Medical Center, National Hospital Organization Sendai Medical Center, Kanto Rosai Hospital, and Hiroshima Prefectural Hospital. All investigations were conducted according to the principles expressed in the Declaration of Helsinki.

For the analysis of *CDH23* mutations, we selected subjects who did not have hearing loss owing to environmental causes and who had participated in a genetic study at our institutes, with each subject meeting the following criteria: 1) sporadic or recessively inherited hearing loss; 2) bilateral non-syndromic congenital hearing loss; 3) a lack of cochlear malformations among those who underwent a computed tomography scan and/or magnetic resonance imaging; 4) a poorer hearing level at high frequencies (e.g., 2 kHz, 4 kHz) than at low frequencies (e.g., 250 kHz, 500 Hz); and 5) severe or profound hearing loss over 70 dB at frequencies exceeding 2 kHz. These clinical features were based on the reported phenotypes of DFNB12 and USH1D \[[@CR12],[@CR14]-[@CR16]\]. Before patient selection for *CDH23* mutation analysis, genetic analyses for *GJB2* and mitochondrial m.1555A \> G and m.3243A \> G mutations were conducted in all patients, according to published methods \[[@CR17],[@CR18]\]. Among 621 probands who participated in a genetic study at our institutes from November 2008 to June 2012 (the first subject group), 72 subjects were selected for *CDH23* mutation analysis based on these criteria.

For *CDH23* analysis, DNA was extracted from peripheral blood using standard procedures. We PCR-amplified all *CDH23* exons using the primers listed in Additional file [1](#MOESM1){ref-type="media"}: Table S1. The PCR products were purified and subjected to sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, CA, USA). SeqScape 2.6 software (Applied Biosystems) was used to analyze data against an NCBI human primary reference sequence (GRCh37.p13). Before SeqScape 2.6 analysis, all known *CDH23* mutations within 69 coding regions and flanking 10-bp sequences of transcript variant 1 archived in the BIOBASE HGMD database (last visited on October 2014; BIOBASE, MA, USA) were entered into the SeqScape project files to enable detection of novel variants. Descriptions of DNA and amino acid positions in the literature \[[@CR6]-[@CR10],[@CR12],[@CR14],[@CR19]\] and the HGMD database were reassigned through original test programs to present the information in a consistent format. Prediction of the effect of missense variants on CDH23 protein function was performed using Polymorphism Phenotyping \[PolyPhen2 \[[@CR20]\] and Protein Variation Effect Analyzer (PROVEAN v1.1.3.) \[[@CR21]\].

Frameshift (splice site within ± 2) and nonsense mutations were categorized as pathogenic. The pathogenicity of splice site alterations larger than ± 2 was predicted by NNSPLICE 0.9 version \[[@CR22]\]. Novel missense variants were defined as pathogenic if they were 1) non-synonymous; 2) exhibited a low carrier rate (\<1%) in 96 normal in-house control Japanese subjects and in public databases \[(dbSNP135 \[[@CR23]\], 1000GENOME \[[@CR24]\], and NHLBI Exome Variant Server \[[@CR25]\]\]; 3) exhibited high amino acid conservation among 12 primate, 45 mammal, and 43 vertebrate species using UCSC Conservation \[[@CR26]\]; 4) demonstrated consistency with phenotypes in family members; and 5) were detected in patients with hearing loss identified as heterozygous in association with another previously reported or determined heterozygous mutation. Variants who failed to meet criteria 1--4 were defined as non-pathogenic. Those who met criteria 1--4 but failed to fulfill criterion 5 were considered to have uncertain pathogenicity. For the purpose of this study, frameshift, splice site, and nonsense mutations were categorized as "truncating" mutations, and missense and in-frame insertion or deletion mutations were considered "non-truncating" mutations.

In addition, we further examined *CDH23* mutations retrospectively in subjects who participated in a genetic study at our institutes from April 2001 to October 2008 (the second subject group). For this analysis, we selected subjects who had obvious progressive hearing loss as determined by repeated audiometry, profound hearing loss over 80 dB at frequencies above 2 kHz, as well as fulfilling the five aforementioned criteria for the first subject group. For these subjects, we additionally performed Sanger sequencing for *CDH23* mutations.

Results {#Sec3}
=======

In the first subject group, we analyzed a total of 621 probands, and 492 underwent clinical selection for *CDH23* gene testing after excluding individuals with *GJB2* mutations and mitochondrial deafness. Figure [1](#Fig1){ref-type="fig"} presents the study procedure together with the selection process for the primary screening. Using this procedure, 72 subjects were selected for *CDH23* mutation analysis (14.6% of the selected individuals). Homozygous or compound heterozygous *CDH23* mutations were identified in 13 subjects (18.1% of tested subjects), and nine subjects had heterozygous mutations (12.5% of tested subjects).Figure 1Flow chart of the selection and exclusion processes and the number of subjects at each point.

In the second subject group, 546 probands participated in the genetic study. After retrospective selection using the more stringent criteria, 15 subjects were selected. After direct sequencing for *CDH23* mutations, three subjects were identified with homozygous or compound heterozygous pathogenic *CDH23* mutations (20.0% of tested subjects), and three subjects were shown to have heterozygous mutations (20.0% of tested subjects).

A total of 16 pathogenic *CDH23* mutations were found in 56 subjects from 28 families. Homozygous or compound heterozygous pathogenic mutations were found in 21 subjects, which included 16 probands. Heterozygous mutations were found in 12 probands. *CDH23* mutations included 11 previously reported mutations \[p.P240L, p.P346S, p.E956K, p.D1626A, p.Q1716P, p.R2029W, p.R1417W, p.E2438K, p.L2473P, p.R2489H, and c.6712 + 1G \> A \[[@CR7],[@CR12],[@CR14],[@CR27]\], as well as four novel mutations (Table [1](#Tab1){ref-type="table"}). Twelve of the mutations were missense, one was a frameshift and three were splice-site mutations. Fifteen variants were considered to have uncertain pathogenicity (Table [1](#Tab1){ref-type="table"}). These include five variants previously reported as uncertain \[[@CR12],[@CR14],[@CR28],[@CR29]\], as well as 10 novel variants. We also found 49 non-pathogenic *CDH23* variants, including 12 new variants (Additional file [2](#MOESM2){ref-type="media"}: Table S2). All the variants reported in this study were registered in the LOVD-CDH23 database \[[@CR30]\].Table 1**Possible pathologic and uncertain variants found in this studyNumber in probands (in 346 allele)Types of variantsLocationAmino acid changeNucleotide changeGenomic position(Chr10)DomainEvolutionary conservation\*HomozygoteCompound heterozygoteHeterozygoteAllele frequency in normal controlsAllele frequency in ESP6500dbSNP135PolyPhen2 scorePROVEAN scoreNovel or KnownReference**MissenseExon 7p.P240Lc.719C \> T73330641EC311/11, 44/44, 40/404760/1920rs1219083540.999−3.051Known\[[@CR12]\]Exon 11p.P346Sc.1036C \> T73377052-12/12, 42/42, 41/410100/1920None0.989−5.768Known\[[@CR27]\]Exon 16p.G539Dc.1616G \> A73437314EC512/12, 43/43, 42/420100/1900None0.092−4.272NovelExon 18p.D645Gc.1934A \> G73442277EC612/12, 45/45, 42/420100/1920None1.000−5.596NovelExon 25p.E956Kc.2866G \> A73464800EC912/12, 45/45, 42/420400/1920None0.999−2.939Known\[[@CR14]\]Exon 35p.R1417Wc.4249C \> T73498294EC1312/12, 32/44, 0/400010/1920None0.453−1.346Known\[[@CR12]\]Exon 39p.D1626Ac.4877A \> C73537468EC1512/12, 45/45, 41/420100/1920None0.952−5.3Known\[[@CR14]\]Exon 39p.Q1716Pc.5147A \> C73538025EC1612/12, 45/45, 40/410200/1920None0.972−2.68Known\[[@CR12]\]Exon 46p.R2029Wc.6085C \> T73550924EC1912/12, 45/45, 39/400220/1920None0.999−4.659Known\[[@CR12]\]Exon 52p.E2438Kc.7312G \> A73559336EC2312/12, 43/44, 15/410200/1920None0.314−0.383Known\[[@CR14]\]Exon 53p.L2473Pc.7418 T \> C73560448EC2311/11, 45/45, 36/360010/1920None0.998−5.603Known\[[@CR12]\]Exon 53p.R2489Hc.7466G \> A73560496EC2312/12, 45/45, 36/360010/1920rs1419866200.459−1.219Known\[[@CR12]\]FrameshiftExon 48p.L2223Wfsc.6667del C73553352\--0100/1920None\--NovelExon 63p.N3044Tfsc.9129 del G73571123\--0100/1900None\--NovelPutative spice siteIVS11-c.1135-1G \> T73403617-12/12, 41/41, 4/40010/1920None\--NovelIVS48-c.6712 + 1G \> A73553398-712/12, 44/44, 41/410100/1920None\--Known\[[@CR11]\]Uncertain pathogenicity variantsMissenseExon 13p.V424Mc.1270G \> A73405717EC412/12, 44/45, 0/360010/1900rs23052070.557−0.572NovelExon 13p.D428Nc.1282G \> A73405729EC412/12, 39/45, 0/36004\*\*0/1900rs1883762960.103−0.045NovelExon 35p.I1406Vc.4216A \> G73498261EC1312/12, 43/44, 40/40.0011/1890rs1924599840.029−0.304NovelExon 38p.G1583Sc.4747G \> A73501580EC1512/12, 44/44, 41/430010/1920None1.000−4.967NovelExon 40p.V1711Ic.5131G \> A73538009EC1612/12, 29/45, 11/410011/1921/12645rs1816117780.998−0.599Known\[[@CR12]\]Exon 42p.G1799Wc.5395G \> T73544070EC1711/11, 45/45, 42/43001\*\*0/1920None0.998−6.237NovelExon 44p.V1908Ic.5722G \> A73545397EC911/12, 28/45, 33/410010/1920None0.0050.125Known\[[@CR14]\]Exon 48p.D2202Ec.6606C \> A73553291EC2112/12, 45/45, 41/42001\*\*0/1900None1.000−3.068Known\[[@CR28]\]Exon 48p.Q2227Pc.6680A \> C73553365EC2112/12, 44/44, 23/410010/1920None0.729−0.775Known\[[@CR29]\]Exon 57p.D2717Nc.8149G \> A73566009EC2512/12, 45/45, 42/42001\*\*0/1900None0.999−1.909NovelExon 61p.G2912Sc.8734G \> A73569588EC2711/11, 45/45, 42/420010/1920None0.774−2.221Known\[[@CR14]\]Exon 70p.V3343Mc.10027G \> A73574997-12/12, 45/45, 16/37001\*\*0/1880None0.670−0.427NovelPutative splice siteIVS2-c.68-3C \> T73206072-12/12, 40/44, 18/190010/1880rs142456469\--NovelIVS7-c.625-5C \> T73330542-11/12, 41/44, 0/400010/1920None\--NovelIVS52-c.7362 + 10G \> A73559396-12/12, 11/42, 5/200010/1920None\--Novel**\***Evolutionary conservation showed up to 12 primates, 45 mammals, and 43 vertebrates, respectively.\*\*Combination of uncertain pathogenicity variants were counted as heterozygotes, not as compound heterozygotes.

Overlapping audiograms of all 21 subjects with biallelic *CDH23* mutations are shown in Figure [2](#Fig2){ref-type="fig"}. The ages of these patients ranged from 0 to 25 years (median: 5 years). The average hearing level was 90.1 ± 12.3 (SD) dB. The average hearing level at 250 and 500 Hz was 70.5 ± 22.7 dB, whereas that at 2000 and 4000 Hz was 101.9 ± 7.8 dB. In addition, 10 of 21 subjects displayed obvious progressive hearing loss, as assessed by comparing audiograms obtained at younger ages. At the time of this study, no subjects were diagnosed with Usher syndrome, which, in addition to hearing loss, is associated with vestibular dysfunction and visual impairment due to retinitis pigmentosa. Information for vision, fundoscopy, and motor milestones in 21 subjects with biallelic *CDH23* mutations is shown in Table [2](#Tab2){ref-type="table"}.Figure 2Overlapping audiograms of subjects with hearing loss caused by *CDH23* mutations. Overlapping audiograms of the better-hearing ear of 20 subjects with homozygous or compound heterozygous *CDH23* mutations.Table 2**Clinical and genetic data in the patients with biallelic CDH23 mutationsCase ID\*** ^**1**^**Age at the latestexaminationGenotypes\*** ^**2**^**VisionFundoscopyMotor milestones\*** ^**3**^125y11mp.P240L / p.P240LNormalNot doneNormal225y7mp.P240L / p.P240LNormalNot doneNormal325y2mp.P240L / p.P240LNormalNot doneNormal424y2mp.P240L / p.P240LNormalNot doneNormal517y3mp.P240L / p.R2029WNormalNormalNormal614y1mp.E2438K / **p.N3044Tfs**NormalNot doneNormal713y3mp.P240L / p.R2029WMyopiaNormalNormal813y2mp.D1626A / **p.L2223Wfs**NormalNot doneNormal913y1mp.P240L / p.P240LNormalNot doneNormal1011y8mp.P240L / p.P240LNormalNot doneNormal1111y4mp.E2438K / **p.N3044Tfs**NormalNot doneNormal1211y2mp.D645G / p.E956KNormalNot doneNormal139y7mp.P240L / p.E956KMyopiaNormalNormal149y2mp.Q1716P / p.E2438KNormalNot doneNormal158y5mp.P240L / p.E956KNormalNot doneNormal167y3mp.P240L / p.E956KNormalNot doneNormal177y0mp.P240L / p.P240LNormalNot doneNormal186y4mp.P346S / p.Q1716PNormalNot doneNormal205y9mp.P240L / **c.6712 + 1G \> A**NormalNot doneNormal213y10mp.P240L / **c.6712 + 1G \> A**HyperopiaNormalNormal\*^1^Cases were shown in the order of their ages at the latest examination.\*^2^Genotypes written by bold word indicate truncating mutations.\*^3^Motor milestones: Head control \< 4 months, Walking alone \< 14 months.

The most frequent mutation in this study was p.P240L, which is consistent with previous reports of the Japanese population \[[@CR12],[@CR14]\]. The overlapping audiograms illustrated that a high proportion of subjects homozygous for the p.P240L mutation had more severe low frequency hearing loss compared with subjects with non-p.P240L homozygous mutations, indicating a genotype-phenotype correlation (Figure [3](#Fig3){ref-type="fig"}).Figure 3Comparison of hearing levels between individuals homozygous for p.P240L and those with other homozygous mutations. **A**: Overlapping audiograms of subjects with homozygous p.P240L mutations. **B**: Overlapping audiograms of the subjects with non-p.P240L homozygous mutations. The subjects with homozygous p.P240L mutations tended to have more severe hearing loss at lower frequencies.

Five of 21 subjects with biallelic *CDH23* mutations had an allele with a truncating mutation, such as a frameshift or splice-site mutation, in association with a missense mutation on the other allele. The other 16 subjects had biallelic missense mutations. The overlapping audiograms of these subjects revealed no significant differences between the subjects with truncating mutations associated with missense mutations and those with biallelic missense mutations (Figure [4](#Fig4){ref-type="fig"}). The average hearing level of the subjects with an allele featuring truncating mutations associated with missense mutations was 90.3 ± 17.2 dB, whereas that of patients with biallelic missense mutations was 90.0 ± 10.2 dB. Because the number of subjects with truncating mutations was small, this result needs to be confirmed in a future study.Figure 4Comparison of hearing levels between patients with truncating and missense mutations and those with biallelic missense mutations. **A**: Overlapping audiogram of subjects with truncating and missense mutations. **B**: Overlapping audiograms of the subjects with biallelic missense mutations. The patterns of the audiograms were similar.

Discussion {#Sec4}
==========

The present results revealed an extremely high prevalence of *CDH23* mutations among patients with congenital sporadic or recessively inherited high-frequency hearing loss. Among 72 probands presenting with our defined set of clinical features, 13 subjects (18.1%) exhibited homozygous or compound heterozygous *CDH23* mutations. Previously, a large cohort study of a Japanese population (n = 1396) using two-step screening revealed that the frequency of biallelic *CDH23* mutations was only 1.6% in patients with hearing loss \[[@CR14]\]. The higher prevalence of *CDH23* mutations in the present study can be explained by subject selection criteria; these criteria included common clinical features of patients with *CDH23* mutations \[[@CR12],[@CR14],[@CR16]\], in addition to excluding patients with *GJB2* and mitochondrial m.1555A \> G and m.3243A \> G mutations. The present results indicate that *CDH23* mutations should be considered as candidate causes of hearing loss when patients present with clinical features similar to the selection criteria used in this study, which are relatively common among individuals with early childhood hearing loss.

A strategy for clinical genetic diagnosis should consider sensitivity, specificity, and cost. The specificity of Sanger sequencing is known to be extremely high, but the cost of analyzing *CDH23* by Sanger sequencing is also extremely high. The present study revealed that its sensitivity for *CHD23* was 18.1% at best. Considering these data and recent advances in genetic technologies, Sanger sequencing of *CDH23* is not likely to be the most practical clinical test currently available. Recently, we and others have developed genetic tests using next-generation sequencing (NGS) for non-syndromic hearing loss \[[@CR31]-[@CR34]\]. The NGS-based tests can examine almost all known deafness genes simultaneously at a cost similar to that for Sanger sequencing of *CDH23* \[[@CR35],[@CR36]\]. Currently, clinical genetic testing using NGS is available in a limited number of institutes, but these tests will become more widely available in the near future. Because the clinical features of *CDH23* mutation, i.e., congenital sporadic or recessively inherited high-frequency hearing loss, are relatively common and associated with mutations in many deafness genes, genetic tests using NGS would be appropriate for patients presenting with these clinical features.

Progression is reported as an important clinical feature of hearing loss caused by *CDH23* mutations \[[@CR14],[@CR16]\]. In our study, progression of hearing level loss was only noted in 10 of 21 subjects who had biallelic mutations. In the 11 subjects who did not display obvious progressive hearing loss, most were less than 5 years old at the time of this study. In general, it is difficult to demonstrate the progression of hearing loss in early childhood; the observation times for younger patients are shorter and the evaluation is performed using different audiological tests depending on the developmental stages. The results, therefore, tend to be unstable compared with those for adults. We believe these difficulties in proving the progression of hearing loss in early childhood explain why the ratio of progressive hearing loss in the present study was lower than that reported previously \[[@CR14],[@CR16]\], and the ratio of hearing loss progression may be higher in a follow-up study.

This study identified truncating mutations of *CDH23* in combination with heterozygous missense alleles in a Japanese population of patients with non-syndromic deafness. In general, individuals with USH1D mostly carry a truncated CDH23 protein because of nonsense, frameshift, or splice-site mutations, whereas those with DFNB12 usually carry missense mutations \[[@CR7],[@CR10],[@CR13]\]. However, USH1D caused by missense mutations has also been reported \[[@CR37]\]. In addition, it has been reported that the DFNB12 allele is phenotypically dominant to an USH1D allele \[[@CR29]\]. The onset of visual impairment caused by retinitis pigmentosa accompanied by USH1D generally occurs during adolescence \[[@CR9]\]. In this study, the ages of patients with monoallelic truncating mutations were 3--14 years, and none of these patients had biallelic truncating mutations. Therefore, at present we cannot determine whether these patients have DNFB12 or USH1D, although all clinical data are compatible with DFNB12 but not with USH1D. However, the detection of a mild visual phenotype requires patients to be followed with ophthalmoscopy and at least one electroretinography. This will provide more precise genotype-phenotype correlations.

Conclusions {#Sec5}
===========

Our results revealed that *CDH23* mutations are highly prevalent in patients with congenital high-frequency sporadic or recessively inherited hearing loss and that the mutation spectrum was diverse, indicating that patients with these clinical features would merit genetic analysis.
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